AnaCardio Announces Completion of Target Enrollment in Phase 2a Study of AC01 in Heart Failure; Results Expected Year-end 2025
Stockholm, Sweden, September 16, 2025 – AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents for heart failure, today announced that its ongoing Phase 2a study of AC01 in patients with heart failure and reduced ejection fraction (HFrEF) is fully enrolled and remains on track to report results by year-end 2025. In the Phase 2a […]
AnaCardio strengthens leadership team with appointment of Philipp Mathieu as Chief Financial Officer
Stockholm, Sweden, September 2, 2025 – AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing novel contractile agents to treat patients with heart failure, announces today the appointment of Philipp Mathieu as Chief Financial Officer (CFO). Philipp is an experienced healthcare executive with two decades of leadership and investment experience across European and US markets. […]
AnaCardio announces positive scientific advice from the FDA and EMA, establishing a favourable development path for AC01 treatment of chronic HFrEF
Alignment reached with both the FDA and EMA on key elements of the AC01 development strategy in chronic HFrEF, allowing for a lean, straightforward and coherent plan across both Europe and the USA AC01, a novel, selective oral ghrelin receptor (GHSR1a) agonist, is currently in Phase IIa (GOAL-HF1) and the advice will enable the planned […]
AnaCardio receives patent grant in Europe for AC01
Stockholm, Sweden and Lugano, Switzerland, March 13, 2025 – AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure and Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of over forty-five years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, today announced […]
AnaCardio reports first patient dosed in the phase 2a study evaluating AC01 in patients with heart failure and reduced ejection fraction (HFrEF)
February 25, 2025, Stockholm, Sweden – AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure today announced that the first patient has been dosed in the phase 2a part of the GOAL-HF1 study evaluating AC01 in patients with HFrEF. AC01 is a novel, selective oral ghrelin receptor (GHSR1a) agonist, […]
AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure
Reports positive results from phase 1b study of AC01 in patients with heart failure and reduced ejection fraction (HFrEF) January 9, 2025, Stockholm, Sweden – AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure today announced the completion of a USD 19 million (SEK 205 million) Series A extension […]
AnaCardio successfully completes first part of AC01 HFrEF study and provides a clinical update
Stockholm, Sweden, September 17, 2024 AnaCardio, a Swedish clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure, today announced that the clinical conduct of the first part of its GOAL-HF1 study in patients with heart failure and reduced ejection fraction (HFrEF) has been completed. Part A of GOAL-HF1 is a randomized, […]
Michael Grissinger appointed as new Chairman of AnaCardio
Stockholm, Sweden, June 3, 2024 AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing novel contractile agents to treat patients with heart failure, announces today the appointment of Michael Grissinger, B.S M.B.A. as new chairman of the board. Michael has had a long and successful career in the pharmaceutical industry, leading large value business development transactions […]
AnaCardio selected as finalist at the J.P. Morgan Asset Management: Life Sciences Innovation Summit
Stockholm, Sweden, April 4 , 2024 AnaCardio, a Swedish clinical-stage biopharmaceutical company focused on developing novel contractile agents to treat patients with heart failure, announced today that it has been selected as one of 11 finalists to present at the inaugural J.P. Morgan Asset Management: Life Sciences Innovation Summit. The summit will take place on […]
AnaCardio appoints Elin Rosendahl as CDO
Stockholm, Sweden, April 3, 2024 AnaCardio AB announces today the appointment of Elin Rosendahl, MSc as Chief Development Officer (CDO). Elin has more than 20 years of experience in managing global biopharmaceutical development programs and leading global cross-functional teams in both small and large pharma companies, and joins AnaCardio from her previous role as Vice […]